{"id":"phenbenzamine","rwe":[{"pmid":"13489166","year":"1957","title":"The action of 5-hydroxytryptamine and some of its antagonists on the umbilical vessels of the human placenta.","finding":"","journal":"British journal of pharmacology and chemotherapy","studyType":"Clinical Study"}],"tags":[{"label":"phenbenzamine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"lergitin","offLabel":[],"synonyms":["lergitin","phenbenzamine"],"timeline":[],"approvals":[],"brandName":"Lergitin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"phenbenzamine","explanation":"Think of it like a key fitting into a lock. Lergitin is like a key that blocks the action of certain chemicals in the body, but we don't yet know which lock it fits into or what the consequences of blocking those chemicals might be.","oneSentence":"Lergitin works by blocking certain receptors in the body, although the specific receptors and pathways involved are not well understood.","technicalDetail":"Phenbenzamine is a non-selective alpha-adrenergic receptor antagonist, which means it can block the action of various neurotransmitters that bind to alpha-adrenergic receptors, potentially affecting blood pressure, heart rate, and other physiological responses."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/225","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=phenbenzamine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:18:01.009891","biosimilars":[],"competitors":[],"genericName":"phenbenzamine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"733W48NG2Q","CHEBI":"CHEBI:135041","PUBCHEM_CID":"13751"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"1957 Dec","pmid":"13489166","title":"The action of 5-hydroxytryptamine and some of its antagonists on the umbilical vessels of the human placenta.","journal":"British journal of pharmacology and chemotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Lergitin (phenbenzamine) is a small molecule drug of the phenbenzamine class. Its mechanism of action is not well established, and it is not FDA approved for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand the properties and potential uses of Lergitin. Due to its lack of FDA approval, it is not currently available as a prescription medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}